Carfilzomib for Injection 30mg
CARFLIEVA 30MG (Carfilzomib for Injection 30mg) is a specialized anticancer medicine used in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. It contains Carfilzomib, a highly effective proteasome inhibitor that helps slow down and control the growth of cancer cells in the body. This oncology injection is commonly prescribed by healthcare professionals as part of advanced chemotherapy and targeted cancer treatment protocols.
Multiple myeloma develops when abnormal plasma cells multiply uncontrollably inside the bone marrow. These cancerous cells interfere with the normal production of blood cells and can weaken bones, reduce immunity, and affect kidney function. CARFLIEVA 30MG works by targeting and blocking proteasomes, which are responsible for breaking down proteins inside cancer cells. When proteasomes are inhibited, cancer cells accumulate damaged proteins and eventually die, helping reduce the spread of the disease.
CARFLIEVA 30MG is widely used in modern oncology treatment because of its effectiveness in managing relapsed or refractory multiple myeloma. It is often prescribed for patients who have previously received other cancer therapies but require further treatment support due to disease progression or recurrence. Doctors may use this medicine alone or in combination with other anticancer medicines depending on the patient’s condition and treatment plan.
This Carfilzomib injection is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable clinical performance. The medicine is intended for hospital and oncology center use and should only be administered by trained healthcare professionals under proper medical supervision.
Patients receiving CARFLIEVA 30MG usually undergo regular medical monitoring, blood tests, and health assessments during treatment to help improve treatment outcomes and reduce the risk of complications. Oncology specialists carefully determine the dosage and treatment schedule based on the patient’s overall health, response to therapy, and stage of cancer.
Due to its advanced mechanism of action and targeted cancer therapy approach, CARFLIEVA 30MG has become an important medicine in the management of multiple myeloma and modern hematology-oncology treatment protocols.
View Details
Enzalutamide Tablets 160mg
ENZALIEVA Enzalutamide Tablets 160mg is an advanced anticancer medicine used for the treatment of prostate cancer in adult patients. It contains Enzalutamide, a powerful androgen receptor inhibitor that helps slow down the growth and spread of prostate cancer cells. This medicine is commonly prescribed by oncologists as part of hormone therapy for patients suffering from advanced or metastatic prostate cancer.
Prostate cancer is one of the most common cancers affecting men worldwide. Cancer cells in the prostate often depend on male hormones called androgens, especially testosterone, for growth and survival. Enzalutamide works by blocking the action of these hormones, helping reduce the ability of cancer cells to grow and multiply. Due to its targeted mechanism of action, ENZALIEVA is widely used in modern oncology treatment protocols for prostate cancer management.
ENZALIEVA Enzalutamide Tablets 160mg is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine is commonly recommended in patients with:
Metastatic castration-resistant prostate cancer (mCRPC)
Non-metastatic castration-resistant prostate cancer (nmCRPC)
Metastatic hormone-sensitive prostate cancer (mHSPC)
This anticancer medicine is usually prescribed when prostate cancer continues to progress despite reduced testosterone levels or hormonal treatment. Doctors may use ENZALIEVA alone or in combination with other therapies depending on the patient’s condition, cancer stage, and overall treatment plan.
Enzalutamide Tablets are known for helping improve disease management by delaying cancer progression and supporting overall treatment outcomes. The medicine has become an important part of prostate cancer therapy due to its effectiveness in controlling androgen receptor activity, which plays a major role in prostate cancer growth.
Patients should use this medicine strictly under the supervision of qualified healthcare professionals. Proper medical monitoring and regular health checkups are important during treatment to ensure better response and patient safety.
View Details
Etoposide Injection IP 100 MG
VEPELIEVA Etoposide Injection IP 100MG is a widely used anticancer chemotherapy medicine formulated for the treatment of different types of cancers. It contains Etoposide, an effective oncology medicine that helps slow down or stop the growth of cancer cells in the body. This injection is commonly used in hospitals, cancer treatment centers, and oncology clinics under the supervision of experienced healthcare professionals.
Etoposide belongs to a class of medicines known as topoisomerase inhibitors. It works by interfering with the DNA replication process of rapidly growing cancer cells. By damaging the DNA of these abnormal cells, the medicine helps prevent their growth and spread. Due to its effectiveness in chemotherapy treatment protocols, Etoposide Injection IP 100MG is commonly prescribed in combination with other anticancer medicines for better treatment outcomes.
VEPELIEVA is manufactured under high pharmaceutical quality standards to ensure safety, purity, and effectiveness. The medicine is designed to meet the requirements of modern oncology treatment and is trusted by healthcare professionals for use in multiple cancer therapies.
This oncology injection is mainly recommended for patients diagnosed with cancers such as small cell lung cancer, testicular cancer, leukemia, lymphoma, and other severe malignant conditions. Doctors may prescribe this medicine alone or as part of combination chemotherapy depending on the patient’s medical condition, stage of cancer, and overall treatment plan.
Chemotherapy medicines like VEPELIEVA are an important part of cancer management because they help reduce the spread of cancer cells and improve the effectiveness of treatment protocols. Since cancer cells multiply rapidly, medicines like Etoposide are specially designed to target these abnormal cells and reduce their growth inside the body.
VEPELIEVA Etoposide Injection IP 100MG is intended strictly for medical use and should only be administered by trained healthcare professionals in clinical settings. Patients are advised not to self-administer this injection. Proper medical monitoring, laboratory testing, and regular health assessments are usually recommended during chemotherapy treatment to ensure patient safety and better treatment response.
This anticancer injection is known for its role in advanced oncology treatment plans and is considered an important chemotherapy medicine in cancer care. With proper medical supervision and supportive care, Etoposide Injection can help improve treatment management in cancer patients.
View Details
Ribavirin Capsules 200mg
RIBALIEVA 200MG (Ribavirin Capsules 200mg) is an antiviral medicine used in the treatment and management of certain viral infections. It contains Ribavirin, a well-known antiviral agent that helps reduce the growth and multiplication of viruses inside the body. This medicine is commonly prescribed by healthcare professionals as part of combination antiviral therapy for chronic viral infections, especially hepatitis-related conditions.
Ribavirin works by interfering with the replication process of viruses, helping reduce viral activity and improving treatment effectiveness. Because of its broad antiviral action, Ribavirin Capsules are widely used in modern antiviral treatment protocols under proper medical supervision.
RIBALIEVA 200MG is generally used in combination with other antiviral medicines rather than as a standalone treatment. Doctors may prescribe this medicine depending on the patient’s viral infection type, medical history, liver condition, and overall health status.
This antiviral capsule is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine is intended for use only under the guidance of qualified healthcare professionals. Patients are advised to follow the prescribed treatment schedule carefully to achieve better treatment outcomes.
Chronic viral infections can affect the liver, immune system, and overall health if not managed properly. Antiviral medicines like Ribavirin play an important role in reducing viral load and supporting long-term disease management. RIBALIEVA 200MG is trusted by healthcare professionals as part of advanced antiviral therapy programs and supportive infection management strategies.
Patients using Ribavirin Capsules may require regular health monitoring, blood tests, and liver function assessments during treatment. Doctors may adjust the dosage depending on treatment response and possible side effects. Proper medical supervision is important throughout the therapy period.
Due to its effectiveness in combination antiviral treatment protocols, RIBALIEVA 200MG is widely used in hospitals, clinics, and healthcare centers involved in infectious disease management and antiviral care.
View Details
Entecavir 0.5mg Tablets
ENTELIEVA 0.5MG (Entecavir 0.5mg Tablet) is an antiviral medicine used for the treatment and long-term management of chronic hepatitis B virus (HBV) infection. It contains Entecavir, a highly effective antiviral agent that helps reduce the multiplication of the hepatitis B virus inside the body. This medicine is commonly prescribed by healthcare professionals to help control viral activity, improve liver health, and reduce the risk of liver-related complications.
Hepatitis B is a serious viral infection that affects the liver and may lead to chronic liver disease, liver damage, cirrhosis, or liver failure if not managed properly. ENTELIEVA 0.5MG works by blocking the replication process of the hepatitis B virus, helping lower the viral load and slowing the progression of the infection.
Entecavir belongs to a class of medicines known as nucleoside analog antiviral agents. It is widely used in modern antiviral treatment protocols because of its effectiveness in controlling chronic hepatitis B infection in adults and eligible patients under medical supervision.
ENTELIEVA 0.5MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. The medicine is trusted by healthcare professionals for use in hospitals, liver care centers, gastroenterology clinics, and infectious disease treatment programs.
Doctors may prescribe this antiviral tablet for patients with:
• Chronic hepatitis B infection
• Active viral replication
• Liver inflammation related to HBV
• Compensated or certain liver-related conditions caused by hepatitis B
This antiviral medicine helps reduce the activity of the hepatitis B virus and supports long-term liver disease management. Patients using ENTELIEVA 0.5MG may require regular liver function tests, viral load monitoring, and medical checkups during treatment.
ENTELIEVA should only be used under the supervision of qualified healthcare professionals. Patients are advised not to stop treatment suddenly without consulting their doctor, as stopping antiviral therapy abruptly may worsen hepatitis B infection in some cases.
Due to its effectiveness in hepatitis B management and antiviral therapy protocols, ENTELIEVA 0.5MG is widely used as part of advanced liver infection treatment and supportive healthcare programs.
View Details
Menotropin Injection 150 IU
ALLIE-HMG 150 IU (Menotropin Injection 150 IU) is a hormonal fertility medicine used in the treatment of infertility in both women and men. It contains Menotropin, also known as Human Menopausal Gonadotropin (HMG), which is a combination of two important reproductive hormones — Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). These hormones play a major role in supporting ovulation in women and sperm production in men.
ALLIE-HMG 150 IU is widely used in fertility treatment programs, IVF procedures, assisted reproductive technology (ART), ovulation induction therapy, and male infertility management. This injection helps stimulate healthy ovarian follicle development in women and supports sperm production in men who have hormonal deficiencies affecting fertility.
Infertility can affect both men and women due to hormonal imbalance, ovulation disorders, low sperm production, or reproductive health complications. Fertility medicines like Menotropin Injection are commonly prescribed by gynecologists, fertility specialists, and infertility experts to improve the chances of conception and reproductive success.
In women, ALLIE-HMG 150 IU works by stimulating the ovaries to produce mature eggs. It is commonly recommended for women who are unable to ovulate properly or who are undergoing fertility procedures such as:
• In Vitro Fertilization (IVF)
• Intrauterine Insemination (IUI)
• Assisted Reproductive Technology (ART)
• Ovulation induction treatment
In men, Menotropin helps stimulate testosterone activity and sperm production, especially in patients with hormonal disorders such as hypogonadotropic hypogonadism and low sperm count.
ALLIE-HMG 150 IU is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended for use only under medical supervision and should be administered by trained healthcare professionals or fertility specialists.
This hormonal injection is commonly used in fertility clinics, IVF centers, gynecology hospitals, and reproductive health treatment programs. Patients undergoing fertility therapy may require regular monitoring through ultrasound scans, hormone testing, and medical evaluation to improve treatment outcomes and reduce complications.
Because fertility treatment plans vary from patient to patient, doctors carefully determine the dosage and treatment schedule depending on age, hormonal condition, reproductive health, and response to treatment.
ALLIE-HMG 150 IU has become an important medicine in modern infertility management due to its effectiveness in supporting reproductive hormone balance and improving fertility treatment success rates.
View Details
Menotropin Injection 75 IU
ALLIE-HMG 75 IU (Menotropin Injection 75 IU) is a fertility hormone injection used in the treatment of infertility in both women and men. It contains Menotropin, also known as Human Menopausal Gonadotropin (HMG), which is a combination of two important reproductive hormones — Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). These hormones play a vital role in supporting ovulation in women and sperm production in men.
ALLIE-HMG 75 IU is widely used in fertility treatment programs, IVF procedures, ovulation induction therapy, assisted reproductive technology (ART), and male infertility management. This hormonal fertility medicine helps stimulate healthy egg development in women and improves sperm production in men who have hormonal deficiencies affecting reproductive health.
Infertility is a common medical condition that can affect couples due to hormonal imbalance, ovulation disorders, low sperm count, reproductive system problems, or other health-related complications. Fertility medicines like Menotropin Injection are commonly recommended by gynecologists, fertility specialists, and IVF experts to improve reproductive function and increase the chances of successful conception.
In women, ALLIE-HMG 75 IU works by stimulating ovarian follicles to grow and mature properly. This process supports ovulation and improves fertility treatment outcomes in women who are unable to ovulate naturally. The injection is frequently used during fertility treatments such as:
• In Vitro Fertilization (IVF)
• Intrauterine Insemination (IUI)
• Ovulation induction therapy
• Assisted Reproductive Technology (ART)
In men, Menotropin helps stimulate the testes to support sperm production and reproductive hormone activity. Doctors may prescribe this medicine for male infertility conditions associated with hormonal deficiency and low sperm production.
ALLIE-HMG 75 IU is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. This injection is intended strictly for medical use and should only be administered under the supervision of trained healthcare professionals or fertility specialists.
Patients undergoing fertility treatment with Menotropin Injection may require regular ultrasound monitoring, hormone testing, and medical assessments during therapy. Fertility specialists carefully evaluate the patient’s response to treatment in order to adjust dosage and improve treatment success rates.
Due to its effectiveness in reproductive hormone therapy and infertility management, ALLIE-HMG 75 IU has become an important medicine in modern fertility treatment protocols and reproductive healthcare programs.
View Details
Ibrutinib Capsules 140mg
IBRULIEVA 140 MG (Ibrutinib Capsules 140 mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Ibrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down and control the growth of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists for the management of chronic blood-related malignancies and advanced lymphoma conditions.
Ibrutinib works by targeting specific proteins responsible for the growth and survival of cancer cells. By blocking BTK activity, the medicine interferes with cancer cell signaling pathways and helps reduce the spread of abnormal B-cells. Due to its targeted mechanism of action, IBRULIEVA 140 MG has become an important medicine in modern hematology-oncology treatment protocols.
This targeted therapy capsule is widely used in the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Chronic Graft Versus Host Disease (cGVHD)
Doctors may prescribe IBRULIEVA alone or in combination with other oncology medicines depending on the patient’s medical condition, stage of cancer, treatment history, and response to therapy.
IBRULIEVA 140 MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine is intended strictly for medical use and should only be taken under the supervision of qualified healthcare professionals.
Blood cancers and lymphatic malignancies can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted cancer therapies like Ibrutinib help improve disease management by specifically targeting cancer-related pathways without affecting healthy cells as extensively as traditional chemotherapy.
Patients receiving IBRULIEVA 140 MG may require regular blood tests, medical monitoring, and health assessments during treatment to help manage side effects and improve treatment outcomes. Doctors carefully determine dosage and treatment duration based on the patient’s overall condition and treatment goals.
Due to its effectiveness in targeted cancer treatment and hematology care, IBRULIEVA 140 MG is widely used in hospitals, oncology centers, hematology clinics, and advanced cancer treatment programs.
View Details
Melphalan Tablet IP 2mg
MELIEVA 2 MG (Melphalan Tablet IP 2 mg) is an anticancer chemotherapy medicine used in the treatment and management of multiple myeloma, ovarian cancer, and certain other cancer-related conditions. It contains Melphalan, a well-known alkylating agent that helps destroy cancer cells by interfering with their DNA and preventing them from multiplying inside the body.
Melphalan is widely used in oncology and hematology treatment programs because of its effectiveness in slowing the growth and spread of abnormal cancer cells. This medicine is commonly prescribed by oncologists as part of chemotherapy treatment protocols for patients requiring long-term cancer management and supportive oncology care.
Cancer cells grow and divide rapidly, affecting normal body functions and overall health. MELIEVA 2 MG works by damaging the genetic material of cancer cells, which reduces their ability to survive and reproduce. This targeted effect helps control cancer progression and supports modern chemotherapy treatment strategies.
MELIEVA 2 MG is mainly used in:
• Multiple myeloma treatment
• Ovarian cancer management
• Bone marrow-related cancer conditions
• Advanced oncology treatment programs
• Certain hematological disorders under specialist supervision
This anticancer medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology treatment.
Doctors may prescribe MELIEVA alone or in combination with other chemotherapy medicines depending on the patient’s medical condition, cancer type, stage of disease, and response to therapy.
Patients receiving Melphalan therapy may require regular blood tests, bone marrow monitoring, liver function assessments, and medical evaluations during treatment. Chemotherapy medicines can affect healthy cells along with cancer cells, so close medical supervision is important for improving treatment outcomes and reducing complications.
Due to its effectiveness in oncology and hematology care, MELIEVA 2 MG has become an important medicine in cancer treatment protocols and long-term chemotherapy management programs.
View Details
Aprepitant Capsules IP 125mg
APRELIEVA 125 MG (Aprepitant Capsules IP 125 mg) is an antiemetic medicine used to help prevent nausea and vomiting caused by chemotherapy treatment and certain medical procedures. It contains Aprepitant, a neurokinin-1 (NK1) receptor antagonist that works by blocking specific signals in the brain responsible for triggering nausea and vomiting.
Cancer patients undergoing chemotherapy often experience severe nausea and vomiting as side effects of anticancer treatment. These symptoms can affect overall health, appetite, energy levels, and quality of life. APRELIEVA 125 MG is specially formulated to help reduce chemotherapy-induced nausea and vomiting (CINV), making cancer treatment more manageable and comfortable for patients.
Aprepitant works differently from traditional anti-nausea medicines. It targets substance P, a natural chemical in the brain associated with the vomiting reflex. By blocking NK1 receptors, APRELIEVA helps prevent both acute and delayed nausea and vomiting that may occur during or after chemotherapy sessions.
This medicine is commonly prescribed along with other antiemetic medicines such as:
• Ondansetron
• Dexamethasone
• Other supportive cancer care medicines
APRELIEVA 125 MG is widely used in:
• Chemotherapy-induced nausea prevention
• Delayed vomiting prevention after chemotherapy
• Supportive oncology care
• Cancer treatment management programs
• Certain surgery-related nausea prevention protocols under medical supervision
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and reliable therapeutic performance. APRELIEVA should only be used under the guidance of qualified healthcare professionals.
Doctors may prescribe this medicine before chemotherapy sessions to help improve patient comfort and treatment tolerance. Effective nausea management is important because uncontrolled vomiting may lead to dehydration, weakness, nutritional problems, and difficulty continuing cancer treatment.
Patients using APRELIEVA 125 MG may require individualized dosing schedules depending on the type of chemotherapy, severity of symptoms, and overall treatment plan. Proper medical supervision helps improve treatment effectiveness and reduce complications.
Due to its effectiveness in supportive oncology care and chemotherapy-related symptom management, APRELIEVA 125 MG has become an important medicine in modern cancer care protocols.
View Details
Acalabrutinib Capsules 100mg
ACALIEVA 100MG (Acalabrutinib Capsules 100mg) is a targeted anticancer medicine used in the treatment of certain blood cancers and lymphatic system cancers. It contains Acalabrutinib, a highly effective Bruton's Tyrosine Kinase (BTK) inhibitor that helps slow down the growth and spread of abnormal cancer cells in the body. This medicine is commonly prescribed by oncologists and hematology specialists as part of advanced cancer treatment protocols for chronic blood-related malignancies.
Acalabrutinib works by blocking the activity of BTK proteins that are involved in the growth and survival of cancerous B-cells. By interrupting these cancer cell signaling pathways, ACALIEVA 100MG helps reduce the multiplication and survival of abnormal cells, supporting long-term cancer management and disease control.
This targeted therapy medicine is widely used in modern hematology-oncology treatment because of its precision-based mechanism and effectiveness in managing blood cancers with fewer effects on healthy cells compared to some traditional chemotherapy medicines.
ACALIEVA 100MG is mainly prescribed for the treatment of:
• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Certain relapsed or refractory blood cancers
• Advanced hematology-oncology treatment programs
Doctors may prescribe Acalabrutinib Capsules alone or in combination with other anticancer medicines depending on the patient’s condition, stage of disease, previous treatment history, and response to therapy.
Blood cancers can affect the immune system, bone marrow, lymph nodes, and overall health. Targeted therapy medicines like Acalabrutinib help control cancer progression by specifically targeting cancer-related proteins responsible for abnormal B-cell growth.
ACALIEVA 100MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and reliable therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology treatment.
Patients undergoing treatment with ACALIEVA may require regular blood tests, medical monitoring, infection screening, and overall health assessments during therapy. Proper monitoring helps improve treatment effectiveness and reduce the risk of complications or serious side effects.
Due to its effectiveness in targeted cancer therapy and hematology care, ACALIEVA 100MG has become an important medicine in modern oncology treatment protocols and long-term blood cancer management programs.
View Details
Erlotinib Tablets IP 150mg
ERLOLIEVA 150 MG (Erlotinib Tablets IP 150mg) is a targeted anticancer medicine used in the treatment of certain types of lung cancer and pancreatic cancer. It contains Erlotinib Hydrochloride, a highly effective Epidermal Growth Factor Receptor (EGFR) inhibitor that helps slow down the growth and spread of cancer cells in the body. This medicine is commonly prescribed by oncologists as part of modern targeted cancer therapy protocols for patients with specific cancer types and genetic profiles.
Cancer develops when abnormal cells grow uncontrollably and spread to other parts of the body. In some cancers, proteins known as Epidermal Growth Factor Receptors (EGFR) play an important role in helping cancer cells survive, multiply, and spread. ERLOLIEVA 150 MG works by blocking these receptors, thereby interfering with cancer cell growth and reducing tumor progression.
Unlike traditional chemotherapy, Erlotinib is a targeted therapy that focuses on specific pathways involved in cancer development. This targeted approach helps improve treatment effectiveness in eligible patients while minimizing damage to healthy cells. As a result, Erlotinib has become an important treatment option in oncology care, especially for patients with EGFR-positive cancers.
ERLOLIEVA 150 MG is commonly prescribed for:
• Non-Small Cell Lung Cancer (NSCLC)
• EGFR Mutation-Positive Lung Cancer
• Advanced or Metastatic Lung Cancer
• Pancreatic Cancer (in combination with other treatments)
• Long-term targeted oncology treatment programs
This medicine may be used as a first-line treatment or after other cancer therapies depending on the patient's condition, treatment history, and medical requirements.
ERLOLIEVA 150 MG is manufactured under strict pharmaceutical quality standards to ensure safety, purity, and consistent therapeutic performance. It is intended strictly for use under the supervision of qualified healthcare professionals experienced in oncology treatment.
Patients receiving Erlotinib therapy may require regular medical monitoring, blood tests, liver function assessments, and imaging studies during treatment. Proper monitoring helps evaluate treatment response and manage potential side effects effectively.
Due to its effectiveness in targeted oncology therapy, ERLOLIEVA 150 MG has become an important medicine in modern cancer care and personalized treatment programs.
View Details
